| [6] |
Geppetti P，Benemei S，De Cesaris F.CGRP receptors and TRP channels in migraine[J].J Headache Pain，2015，16（Suppl 1）：A21.
|
| [10] |
Edvinsson L.The trigeminovascular pathway：role of CGRP and CGRP receptors in migraine[J].Headache，2017，57（Suppl 2）：47-55.
|
| [1] |
Gonzalez-Hernandez A，Marichal-Cancino BA，Lozano-Cuenca J，et al.Heteroreceptors modulating CGRP release at neurovascular junction：potential therapeutic implications on some vascular-related diseases[J].Biomed Res Int，2016，2016：2056786.
|
| [2] |
Iyengar S，Ossipov MH，Johnson KW.The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine[J].Pain，2017，158（4）：543-559.
|
| [3] |
Deen M，Correnti E，Kamm K，et al.Blocking CGRP in migraine patients-a review of pros and cons[J].J Headache Pain，2017，18（1）：96.
|
| [4] |
Lee SM，Hay DL，Pioszak AA.Calcitonin and amylin receptor peptide interaction mechanisms：Insights into peptidebinding modes and allosteric modulation of the calcitonin receptor by receptor activity-modifying proteins[J].Biol Chem，2016，291（16）：8686.
|
| [5] |
Johansson E，Hansen JL，Hansen AM，et al.Type II Turn of Receptor-bound salmon calcitonin revealed by X-ray crystallography[J].J Biol Chem，2016，291（26）：13689-13698.
|
| [7] |
Bigal ME，Escandon R，Bronson M，et al.Safety and tolerability of LBR-101，a humanized monoclonal antibody that blocks the binding of CGRP to its receptor：results of the Phase 1 program[J].Cephalalgia，2014，34（7）：483-492.
|
| [8] |
Schuster NM，Rapoport AM.Calcitonin gene-related peptide-targeted therapies for migraine and cluster headache：a review[J].Clin Neuropharmacol，2017，40（4）：169-174.
|
| [9] |
Hansen JM，Hauge AW，Olesen J，et al.Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura[J].Cephalalgia，2010，30（10）：1179-1186.
|
| [11] |
Katafuchi T，Yasue H，Osaki T，et al.Calcitonin receptorstimulating peptide：its evolutionary and functional relationship with calcitonin/calcitonin gene-related peptide based on gene structure[J].Peptides，2009，30（9）：1753-1762.
|
| [12] |
Ho TW，Connor KM，Zhang Y，et al.Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention[J].Neurology，2014，83（11）：958-966.
|
| [13] |
Recober A，Kuburas A，Zhang Z，et al.Role of calcitonin gene-related peptide in light-aversive behavior：implications for migraine[J].J Nenros，2009，29（27）：8798-8804.
|
| [14] |
Tfelt-Hansen P，Olesen J.Possible site of action of CGRP antagonists in migraine[J].Cephalalgia，2011，31（6）：748-750.
|
| [15] |
Olesen J，Diener HC，Husstedt IW，et al.Calcitonin generelated peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine[J].N Engl J Med，2004，350（11）：1104-1110.
|
| [16] |
Connor KM，Shapiro RE，Diener HC，et al.Randomized，controlled trial of telcagepant for the acute treatment of migraine[J].Neurology，2010，74（12）：1007-1008.
|
| [17] |
Hewitt DJ，Aurora SK，Dodick DW，et al.Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine[J].Cephalalgia，2011，31（6）：712-722.
|
| [18] |
Barbanti P，Aurilia C，Fofi L，et al.The role of anti-CGRP antibodies in the pathophysiology of primary headaches[J].Neurol Sci，2017，38（Suppl 1）：31-35.
|
| [19] |
Bigal ME，Dodick DW，Rapoport AM，et al.Safety，tolerability，and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine：a multicentre，randomised，double-blind，placebo-controlled，phase 2b study[J].Lancet Neurol，2015，14（11）：1081-1090.
|
| [20] |
Ashina H，Newman L，Ashina S.Calcitonin gene-related peptide antagonism and cluster headache：an emerging new treatment[J].Neurol Sci，2017，38（12）：2089-2093.
|
| [21] |
Dodick DW，Goadsby PJ，Silberstein SD，et al.Safety and efficacy of ALD403，an antibody to calcitonin gene-related peptide，for the prevention of frequent episodic migraine：a randomised，double-blind，placebo-controlled，exploratory phase 2 trial[J].Lancet Neurol，2014，13（11）：1100-1107.
|
| [22] |
Hong P，Wu X，Liu Y.Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine：a meta analysis[J].Clin Neurol Neurosurg，2017，154：74-78.
|
| [23] |
Sun H，Dodick DW，Silberstein S，et al.Safety and efficacy ofAMG334forpreventionofepisodicmigraine：arandomised，double-blind，placebo-controlled，phase 2 trial[J].Lancet Neurol，2016，15（4）：382-390.
|
| [24] |
Dodick DW，Ashina M，Brandes JL，et al.Arise：a Phase 3 randomized trial of erenumab for episodic migraine[J].Cephalalgia，2018，38（6）：1026-1037.
|
| [25] |
Tepper S，Ashina M，Reuter U，et al.Safety and efficacy of erenumabforpreventivetreatmentofchronicmigraine：a randomised，double-blind，placebo-controlled phase 2 trial[J].Lancet Neurol，2017，16（6）：425-434.
|
| [26] |
Tso AR，Goadsby PJ.Anti-CGRP monoclonal antibodies：the next era of migraine prevention?[J].Curr Treat Options Neurol，2017，19（8）：27.
|
